Ciblex is developing small molecule drugs to block the export of a group disease-associated proteins which are not secreted in the usual manner ("exported proteins"). Secreted proteins cannot normally be blocked at their source because it is impossible to block an undesireable protein without also blocking all other proteins. Exported proteins, the company believes, can be selectively blocked.